Intense competition in sacropelvic and spine implants
Surgeons can choose alternative products based on evidence, ease of use, and reimbursement.
- Scope
- Core U.S. implant franchise
- Materiality
- high
SI-BONE, Inc.
SI-BONE, Inc. develops and commercializes implant systems and surgical instruments for sacropelvic conditions, with a core focus on minimally invasive treatment of sacroiliac joint dysfunction and degeneration. The company is based in the United States and sells through direct and partner sales channels in the U.S. and selected international markets, including Europe.
−8,2 %
79,6 %
−9,4 %
+20,2 %
8.55
7.21
| % | |
|---|---|
| Sacroiliac joint fusion systems | 55% Minimally invasive implants and instruments used to treat sacroiliac joint dysfunction and degeneration. |
| Thoracolumbar fixation and fusion | 20% Implant systems designed for adult spinal deformity and thoracolumbar stabilization procedures. |
| Pelvic trauma fixation | 15% Implants and tools used in pelvic fracture fixation and trauma-related procedures. |
| Implantable bone products and accessories | 10% Adjunct bone products, instruments, and procedure support items used with the implant portfolio. |
SI-BONE sells primarily to surgeons and hospitals that perform minimally invasive sacropelvic and spine procedures...
- Orthopedic and spine surgeonsprimary
Buy implant systems and instruments for sacroiliac fusion, spinal fixation, and pelvic trauma procedures because they need clinically supported, anatomy-specific solutions.
- Hospitals and surgical facilitiesprimary
Purchase or consignment-use trays, implants, and procedure support items to enable cases and maintain inventory availability.
- Healthcare systems and payorssecondary
Influence adoption through reimbursement coverage and payment policies that affect procedure economics.
- International distributors and resellerssecondary
Buy or distribute products in non-U.S. markets where SI-BONE uses a mixed direct and partner model.
The United States is the company’s core market and accounted for 95% of revenue in 2025, with international markets...
- •United States generated 95% of 2025 revenue
- •International revenue was 5% of 2025 revenue
- •Direct sales force is concentrated in the U.S.
- •Europe is the main disclosed international operating region
- •Revenue is billed by customer address, not procedure site
SI-BONE’s strategy centers on expanding procedure volume by broadening its product portfolio and increasing the number...
01
Grow procedure volume through portfolio expansionmedium-term
More indications and product lines increase the number of cases a surgeon can treat with SI-BONE systems.
02
Improve commercial productivityshort-term
Higher sales-force efficiency supports broader physician coverage without proportional overhead growth.
03
Strengthen supply and manufacturing executionshort-term
Reliable implant availability and lower rework are important in procedure-driven medical device sales.
SI-BONE faces competition from other implant and spine companies, and adoption depends on clinical evidence,...
Supply-chain and sterilization disruptions
The company relies on third-party suppliers for materials, components, and sterilization services.
- Scope
- Product availability and case fulfillment
- Materiality
- high
Regulatory scrutiny of physician financial relationships
Consulting, royalty, and co-marketing arrangements may be challenged under anti-kickback laws.
- Scope
- Commercial relationships and compliance
- Materiality
- high
Cybersecurity and data privacy incidents
A breach could expose confidential information, disrupt systems, and create legal liability.
- Scope
- IT systems and sensitive data
- Materiality
- medium
Sales-force retention and productivity risk
The model depends on trained reps and agents who support surgeons and case coverage.
- Scope
- Commercial execution
- Materiality
- medium
Revenue recognition
Quarterly revenue timing and comparability
Seasonality
Quarterly trend interpretation
Inventory and instrument tray capitalization
Working capital and gross margin
Estimates and judgments
Reported earnings and balance-sheet values
: 29.4.2026